Interaction with Calcium-Containing Solution
Patients, who use calcium-containing solution to prepare the injection are at high risk. When the injection of this medicine is prepared with calcium-containing solutions, then it may lead to an increased risk of formation of solid calcium
particles. Do not use calcium-containing solutions (such as Ringer’s solution or Hartmann’s solution) for preparing the injection.
Patients receiving cephalosporins are at an increased risk of abnormal breakdown of red blood cells (hemolytic anemia
). Such patients may see an increased risk of fatal conditions both in adults and children. If this happens, stop using this medicine until its cause is determined.
Use of Antibacterial Medicines
Patients who use antibacterial medicines including Pan-Ceftriaxone are at increased risk. In such patients, severe diarrhea
may occur which is caused by Clostridium difficile bacteria. If this happens, stop using this medicine and take protein supplements or maintain the balance
of body fluid and electrolyte (example sodium
, chloride, potassium
, and bicarbonate).
Long-Term Treatment with Pan-Ceftriaxone
Patients on long-term treatment with cephalosporins are at an increased risk when using this medicine. In such patients, complete blood count should be checked regularly.
Use of Pan-Ceftriaxone Sodium
Patients, who use Pan-Ceftriaxone sodium
are at increased risk. Such patients should follow a controlled sodium diet
Treatment With Pan-Ceftriaxone
Patients treated with this medicine are at an increased risk of inflammation of the pancreas (pancreatitis
Patients with a history of kidney stone and excessive urinary calcium
excretion are at an increased risk when using this medicine. In such patients, the kidney stone may occur upon discontinuation of Pan-Ceftriaxone.
Abnormal Functioning of the Liver and Kidneys
Such patients are at an increased risk when using this medicine. Careful clinical monitoring of safety
and efficacy data is advisable for Pan-Ceftriaxone.
Allergy to Pan-Ceftriaxone
Patients who are allergic to Pan-Ceftriaxone are at an increased risk. Such patients may see an increased risk of life-threatening allergic reactions such as Stevens-Johnson syndrome
or Lyell's syndrome. These patients should discontinue the use of this medicine.
Interference with Serological Testing
Use of Pan-Ceftriaxone may lead to false positive results for the determination of glucose in urine. An alternative testing method should be followed to avoid false positive results.